FeesSafety
Pluang+

Cohen & Steers Closed-End Opportunity Fund offers steady 9% returns with an 11.4% discount on assets in 2026.

Market News
28 Sep 2026
Seeking Alpha
View Source
Bullish
Cohen & Steers Closed-End Opportunity Fund offers steady 9% returns with an 11.4% discount on assets in 2026.

Steven Bavaria highlights Cohen & Steers Closed-End Opportunity Fund as his 2026 top pick due to its resilience amid economic uncertainty. The fund has delivered an average 9% total return over the past 10-15 years with a consistent monthly distribution since 2010. Currently, the fund trades at an 11.4% discount on its underlying assets, providing an attractive buying opportunity. Bavaria emphasizes the fund's steady income and the added value of this "discount on discounts" for investors seeking reliable returns.

Cohen & Steers Closed-End Opportunity Fund is the subject, with Pluang market data providing context. For readers following US stocks, here is Pluang's market snapshot as of Sep 28, 2026 21:51 WIB: out of 150 priced US stocks, 34 rose and 116 fell. Intel Corp (INTC) traded at USD 115.66 with a 1-day change of -5.97%, AMC Entertainment Holdings (AMC) rose 5.78% to USD 3.11, and Plug Power Inc (PLUG) fell 5.05% to USD 1.88. Typical hold times on Pluang range from 41 to 116 days for these stocks.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
57 minutes ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
57 minutes ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
Trump adjusts Canada tariffs days before midterms, adding more items than removing.

Trump adjusts Canada tariffs days before midterms, adding more items than removing.

President Trump signed a proclamation on October 23, 2026, reshuffling which Canadian goods face his 50% tariffs, removing items like plywood and packing crates but adding others such as carpets and vinyl flooring. The broad tariffs on about $20 bill...

Market News
Neutral
4 hours ago
Injective CEO meets US regulators to push for clearer rules on tokenized assets and onchain finance.

Injective CEO meets US regulators to push for clearer rules on tokenized assets and onchain finance.

Injective CEO Eric Chen met with officials from the White House, SEC, and CFTC in October 2026 to discuss advancing regulated onchain finance and tokenization of real-world assets (RWAs) in the US. Injective, registered as a transfer agent by the SEC...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App